Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program

Published November 8, 2026 4:00 PM UTC

1 min read

Source: Federal Register — Small Business

This rule finalizes and codifies the Medicare Drug Price Negotiation Program ("Negotiation Program") and establishes certain new policies for the Negotiation Program and the Medicare Prescription Drug Benefit Program ("Part D Program") as required by the Inflation Reduction Act of 2022. This final rule also finalizes a proposed policy for specific fixed combination drugs that are new formulations.

Related coverage